EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy

Michelle C Janelsins iD, Riham A Alieldin iD, Tyler Holler iD, Hongying Sun iD, Po-Ju Lin, Michelle Shayne, Alissa Huston, Kassandra Doyle, Michelle Porto, Mohamedtaki Tejani, Bryan Thompson, Allison Magnuson iD und 15 weitere

Cancer · 2026

DOI: 10.1002/cncr.70323 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Michelle C Janelsins und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Supportive Care in Cancer, University of Rochester, Rochester, New York, USA. Hauptthemen laut MEDLINE: Ibuprofen, Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interventions for cancer‐related cognitive impairment are understudied, particularly during therapy.

Methods

Patients with cancer receiving chemotherapy reporting cognitive problems were randomized to one of four study arms for 6 weeks in this phase 2 randomized controlled trial with a 2 × 2 factorial design. Study arms included: Exercise for Cancer Patients©® (EXCAP)–ibuprofen, EXCAP–placebo, ibuprofen only, and placebo only. EXCAP is a home‐based, low to moderate‐intensity, progressive walking and resistance exercise prescription. Cognitive and biologic assessments were conducted at baseline and post‐intervention.

Results

Eighty‐six participants were randomized (mean age, 53.60; 88.37% female). Between‐group analyses showed that participants in the EXCAP–placebo group demonstrated significantly better attention performance on the Trail Making Test compared to the placebo group (−21.57 seconds, p < .001; Cohen’s d = –1.31; 95% CI, –2.18 to –0.44; lower times indicate better performance). The ibuprofen only group showed greater improvements than the placebo group (−11.27‐second difference, p = 0.05; Cohen’s d = –0.73; 95% CI, –1.57 to 0.11). Both EXCAP–ibuprofen and EXCAP–placebo participants exhibited improvements on the FACT‐Cog “comments from others” compared to placebo (Cohen’s d = 1.00; 95% CI, 0.35 to 1.65 and Cohen’s d = 0.65; 95% CI, –0.01 to 1.31). On Rapid Visual Processing mean latency, participants in the EXCAP‐placebo group had a significant improvement compared to placebo (Cohen's d = −1.10; 95% CI, −1.97 to −0.23); those receiving ibuprofen had an improvement compared to placebo, which revealed a trend after adjusting for reading score (Cohen's d = −1.04; 95% CI, −2.06 to −0.01). The ibuprofen group performed less well on the Hopkins Verbal Learning Test‐Revised delayed compared to those not receiving ibuprofen (Cohen’s d = –0.64; 95% CI, –1.21 to –0.07).

Conclusions

Exercise and low‐dose ibuprofen improved some domains of cognitive function, although effects were not observed across all measures. Phase 3 trials are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IbuprofenNeoplasmsExercise TherapyChemotherapy-Related Cognitive ImpairmentAntineoplastic AgentsAnti-Inflammatory Agents, Non-SteroidalHumansFemaleMiddle AgedMaleAdultCognitive EnhancementAged

Stichwörter der Autor:innen

cancerchemotherapycognitive functionexerciseibuprofen

Substanzen

IbuprofenAntineoplastic AgentsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Surgery, Division of Supportive Care in Cancer, University of Rochester, Rochester, New York, USA.
  • Wilmot Cancer Institute, Rochester, New York, USA.
  • Department of Medicine, University of Rochester, Rochester, New York, USA.
  • Advent Health Cancer Institute, Gainesville, Florida, USA.
  • Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Michelle C Janelsins, Riham A Alieldin, Tyler Holler, Hongying Sun, Allison Magnuson, Ajay Dhakal

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Janelsins, M. C., Alieldin, R. A., Holler, T., Sun, H., Lin, P. J., Shayne, M., Huston, A., Doyle, K., Porto, M., Tejani, M., Thompson, B., Magnuson, A., Krebs, M., Dunne, R. F., Mohile, S. G., Li, C. S., Gada, U., Dhakal, A., Hezel, A. F., …, & Mustian, K. M. (2026). Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy. Cancer. https://doi.org/10.1002/cncr.70323

Vancouver

Janelsins MC, Alieldin RA, Holler T, Sun H, Lin PJ, Shayne M, et al. Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy. Cancer. 2026. doi:10.1002/cncr.70323

BibTeX
@article{Janelsins2026,
  author = {Janelsins, Michelle C and Alieldin, Riham A and Holler, Tyler and Sun, Hongying and Lin, Po-Ju and Shayne, Michelle and Huston, Alissa and Doyle, Kassandra and Porto, Michelle and Tejani, Mohamedtaki and Thompson, Bryan and Magnuson, Allison and Krebs, Marcia and Dunne, Richard F and Mohile, Supriya G and Li, Chin-Shang and Gada, Umang and Dhakal, Ajay and Hezel, Aram F and Noel, Marcus S and Khorana, Alok A and Yirinec, Brian D and Kamath, Nayana and Dougherty, David W and Ahles, Tim A and Morrow, Gary R and Mustian, Karen M},
  title = {Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70323}
}
Kostenlos starten →